Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Mathews

Rheumatology St George, UT Medical Doctor

NPI 1518968015 CMS profile 114470

1490 E Foremaster Dr Ste 220, St George, UT 84790

Open in the dashboard

General payments

$5,161

330 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Mathews of St George, UT is reported in the CMS Open Payments database as having received $5,161 across 330 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $34 1
2024 General $16 1
2023 General $182 11
2022 General $1,488 92
2021 General $814 51
2020 General $946 64
2019 General $1,680 110

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Mathews
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Jeffrey Mathews were reported at $34. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Jeffrey Mathews Rheumatology median Middle half National median
2019 $1,680 $744 $153–$2,687 $163
2020 $946 $462 $98–$2,027 $114
2021 $814 $531 $101–$2,153 $132
2022 $1,488 $627 $125–$2,303 $149
2023 $182 $741 $145–$2,524 $160
2024 $16 $830 $166–$2,660 $164
2025 $34 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $855 54 payments
  2. Janssen Biotech, Inc. $693 44 payments
  3. Amgen Inc. $577 37 payments
  4. Genentech USA, Inc. $487 26 payments
  5. Novartis Pharmaceuticals Corporation $466 32 payments
  6. UCB, Inc. $462 28 payments
  7. Lilly USA, LLC $284 21 payments
  8. GlaxoSmithKline, LLC. $227 14 payments
  9. Pfizer Inc. $173 15 payments
  10. Mallinckrodt Hospital Products Inc. $166 11 payments
  11. Other $771 48 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,894 327 payments
  2. Education $267 3 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $512 28 payments
  2. Cimzia $462 28 payments
  3. Rituxan $450 20 payments
  4. SIMPONI ARIA $448 29 payments
  5. SIMPONI $428 28 payments
  6. STELARA $409 27 payments
  7. COSENTYX $401 28 payments
  8. Actemra $373 24 payments
  9. REMICADE $341 22 payments
  10. HUMIRA $262 20 payments
  11. Other $2,983 195 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$28,617

Medicare's payments for the services billed

Medicare patients

231

Average age 72

Services billed

889

187 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 37%
Depression 33%
Chronic kidney disease 23%
Ischemic heart disease 20%
Diabetes 19%
Heart failure 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

330 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record